Multiple recurrences of acute tumor lysis syndrome in an indolent non-hodgkin's lymphoma
β Scribed by Ralph V. Boccia; Dan L. Longo; Michael L. Lieber; Elaine S. Jaffe; Richard I. Fisher
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 367 KB
- Volume
- 56
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Rituximab, an anti-CD20 antibody, has been recently approved for the treatment of lowgrade or follicular non-Hodgkin's lymphoma (NHL). Because of its relatively benign side effect profile, it has been considered a nontoxic alternative to chemotherapy. Recently, however, tumor lysis syndrome (TLS) re
Acute tumor lysis syndrome occurs in occurring after a sustained episode of high rapidly growing lymphoid malignancies, fever of 42.0" C in a patient with high grade usually as a consequence of chemotherapy lymphoblastic lymphoma and a high tumor or corticosteroids. We present what appears burden. Q
Detection of residual disease in follicular lymphoma is hampered by the observation of t(14;18)-bearing cells in the blood of healthy adult humans. To overcome this problem, we decided to validate a quantification method of t(14;18)bearing cells and test it in t(14;18)-bearing follicular lymphomas (